BOCI raised the target price for Wuxi Bio (02269) to HKD37 from HKD31 and maintained the "buy" rating.
The research house said it forecasts WuXi Bio to deliver revenue growth of 16%/15% YoY in FY26/FY27.
【說說心理話】潛意識治療師分享用催眠自我療癒經歷：由被確定骨枯到坐輪椅，最後更跑了馬拉松！► 即睇
